JW Asset Management
HRTX icon

JW Asset Management’s Heron Therapeutics HRTX Stock Holding History

JW Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$44.2K Sell
140,863
-3,610,210
-96% -$1.37M 0.02% 29
2026
Q2 		$1.6M Hold
3,751,073
– – 0.5% 14
2026
Q1 		$3M Buy
3,751,073
+80,000
+2% +$92.7K 1.23% 11
2025
Q4 		$4.77M Buy
3,671,073
+378,440
+11% +$467K 1.55% 10
2025
Q3 		$4.15M Buy
3,292,633
+954,890
+41% +$1.51M 1.99% 8
2025
Q2 		$4.84M Hold
2,337,743
– – 2.39% 7
2025
Q1 		$5.14M Buy
2,337,743
+45,325
+2% +$88K 2.91% 5
2024
Q4 		$3.51M Hold
2,292,418
– – 1.67% 7
2024
Q3 		$4.56M Hold
2,292,418
– – 2.06% 7
2024
Q2 		$8.02M Hold
2,292,418
– – 3.31% 6
2024
Q1 		$6.35M Hold
2,292,418
– – 2.32% 10
2023
Q4 		$3.9M Sell
2,292,418
-115,000
-5% -$127K 2.22% 9
2023
Q3 		$2.48M Buy
2,407,418
+200,000
+9% +$285K 1.07% 9
2023
Q2 		$2.56M Buy
+2,207,418
New +$3.94M 0.93% 7
2015
Q1 		– Sell
-3,275
Closed -$33K – 50
2014
Q4 		$33K Buy
+3,275
New +$26.7K 0.02% 53

Other funds holding HRTX

Tejara Capital
Tejara Capital London, United Kingdom $205M AUM 0.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Congress Park Capital
Congress Park Capital Saratoga Springs, New York $381M AUM 20.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Apeiron RIA
Apeiron RIA Dallas, Texas $440M AUM 15.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

JW Asset Management's HRTX Position: Q3 2026 in Review

JW Asset Management reduced its Heron Therapeutics (HRTX) stake by 96% in Q3 2026, selling an estimated $1.37M and leaving 140,863 shares worth $44.2K. The position accounts for 0.02% of the portfolio, ranked #29.

JW Asset Management first reported a position in HRTX in Q4 2014 and has held it in 15 quarters since. The position peaked at $8.02M in Q2 2024. 79 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

  • JW Asset Management held 140,863 shares of Heron Therapeutics worth $44.2K as of Q3 2026.
  • JW Asset Management sold 3,610,210 Heron Therapeutics shares in Q3 2026, an estimated $1.37M.
  • Heron Therapeutics made up 0.02% of JW Asset Management's portfolio in Q3 2026, its #29 holding.
  • JW Asset Management first reported a position in Heron Therapeutics in Q4 2014 and has held it in 15 quarters since.
  • JW Asset Management's Heron Therapeutics position peaked at $8.02M in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on JW Asset Management's 13F filing for Q3 2026, filed 6 Nov 2026.